Organogenesis (NASDAQ:ORGO) and Incyte (NASDAQ:INCY) Head to Head Comparison

Incyte (NASDAQ:INCY – Get Free Report) and Organogenesis (NASDAQ:ORGO – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Incyte and Organogenesis, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte 1 13 11 0 2.40
Organogenesis 1 2 0 0 1.67

Incyte currently has a consensus price target of $132.86, indicating a potential upside of 9.17%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 349.05%. Given Organogenesis’ higher possible upside, analysts clearly believe Organogenesis is more favorable than Incyte.

Profitability

This table compares Incyte and Organogenesis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Incyte 6.71% 7.92% 6.12%
Organogenesis -39.34% -55.28% -23.72%

Valuation and Earnings

This table compares Incyte and Organogenesis”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Incyte $5.14 billion 4.82 $1.29 billion $1.88 64.73
Organogenesis $564.17 million 0.22 $37.03 million ($1.22) -0.79

Incyte has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

97.0% of Incyte shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 18.8% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Incyte has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.

Summary

Incyte beats Organogenesis on 10 of the 13 factors compared between the two stocks.

About Incyte

(Get Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

About Organogenesis

(Get Free Report)

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.